Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: GOG 0186I Principal Investigator: Mutch, David
Title: A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) In The Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Phase: II Disease Site: Multiple Sites
Participating Site(s):
 
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The main purpose of this study is to compare the effectiveness of the drug bevacizumab alone to the combination of bevacizumab and the drug fosbretabulin tromethamine (CA4P) in treating your type of cancer and to determine the types and severity of side effects caused by treatment with these drugs.
 
More Information:
Internal Protocol Documents (requires Siteman administrative database password)